Adriamycin ADM and Epirubicin E-ADM 1999.1.7

Adriamycin (ADM) and Epirubicin (E-ADM) 1999.1.7

ADM is a second-generation epirubicin-based anticancer drug. E-ADM is a third-generation epirubicin-based anticancer drug. Both have a broad anticancer spectrum and are suitable for treating tumors in the neck and forehead, soft tissue tumors, kidney cancer, bladder cancer, thyroid cancer, breast cancer, malignant lymphoma, and small cell lung cancer. In general, except for ovarian cancer and testicular cancer, all cancers can be treated. Dosage and administration: For ADM, 10 mg per vial, usually administered once every three weeks at 40–60 mg via intravenous drip; alternatively, 20–30 mg can be given weekly via intravenous drip, diluted in 250 mL of 0.9% sodium chloride solution. For E-ADM, 10 mg per vial, 60–100 mg once every three weeks, or 30 mg once a week. The total dose for ADM is 500 mg, while for E-ADM it is 1000 mg; thus, the former has a smaller total dose, whereas the latter has a larger total dose. Both drugs share the side effect of bone marrow suppression, but E-ADM has greater cardiotoxicity than ADM. Both are DNA intercalators, inhibiting cancer cell division and achieving therapeutic effects. They are effective during both the S phase and the M phase.